TLR7 and systemic lupus erythematosus: Ruzotolimod (TLR7 agonist), demonstrated weak binding, aligning with its profile as an oral immunomodulatory activating TLR7 [67].The afimetoran, alone or in combination with prednisolone, showed efficacy in NZB/W mice lupus model, and successfully reduced sensitivity of bone marrow pDC and B cells to prednisolone induce apoptosis [89], which further support our findings.